Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8444804 | 0.76 | NPC1 (0.34) | TRPA1TRPM8NPC1L3MBTL1 | |
| SCHEMBL2121390 | 0.74 | NOS3 (0.35) | TRPA1TRPM8NPC1L3MBTL1 | |
| Menthone SCHEMBL901274 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 | |
| SCHEMBL6248974 | 0.74 | TRPA1 (0.30) | TRPA1TRPM8NPC1L3MBTL1 | |
| Menthone SCHEMBL13255148 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 | |
| SCHEMBL23332079 | 0.74 | NOS3 (0.31) | TRPA1TRPM8NPC1L3MBTL1 | |
| Rel-Menthone SCHEMBL21711 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 | |
| Menthone SCHEMBL4395963 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 | |
| Menthone SCHEMBL21709 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 | |
| Rel-Menthone SCHEMBL1868327 | 0.74 | TLR4 (0.39) | TRPA1TRPM8NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531547-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | claimed |
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | claimed |
| WO-2024042550-A1 | OPHTHALMIC COMBINATION COMPOSITION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| US-9957613-B2 | Laminate, barrier film and method for manufacturing these | TOPPAN PRINTING CO., LTD. (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-1924564-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20160017491-A1 | LAMINATE, BARRIER FILM AND METHOD FOR MANUFACTURING THESE | TOPPAN PRINTING CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| CN-101296907-B | Diaminopyrimidines as P2X3 and P2X2/3 modulators | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
| WO-2011139842-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING FGFR3 GENE EXPRESSION AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7531547-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| CN-101296907-A | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1112995-B1 | ALICYCLIC COMPOUNDS AND CURABLE RESIN COMPOSITION | NISSAN CHEMICAL IND LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007025899-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| EP-1112995-A1 | ALICYCLIC COMPOUNDS AND CURABLE RESIN COMPOSITION | Nissan Chemical Industries, Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| US-4504478-A | Cephalosporin-1-oxide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1985-03-12 | — | — | US | disclosed |
| EP-0120402-A1 | Base precursor | FUJI PHOTO FILM CO., LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0015274-A1 | IMPROVED ENKEPHALIN DERIVATIVES | KASTIN, Abba J. (US) | 1980-09-17 | — | — | EP | disclosed |
| WO-1980000022-A1 | IMPROVED ENKEPHALIN DERIVATIVES | KASTIN A (US) | 1980-01-10 | — | — | WO | disclosed |
| US-4001068-A | PROCESS FOR SEALING GLASS TO METAL | IMC CHEMICAL GROUP, INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | P2RX3, P2RX1, P2RX2 | TRPA1 129/4885TRPM8 488/4885NPC1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.